Praxis Precision Medicines (NASDAQ:PRAX) Stock Rating Reaffirmed by Truist Financial
Truist Financial reaffirmed their buy rating on shares of Praxis Precision Medicines (NASDAQ:PRAX – Free Report) in a report released on Thursday morning, Benzinga reports. They currently have a $150.00 target price on the stock. A number of other research firms have also recently commented on PRAX. Robert W. Baird initiated coverage on shares of […]
More Stories
Iranian President Says His Country in ‘Full-Fledged War’ With US, Europe, and Israel
By Jack Phillips Iranian President Masoud Pezeshkian said Saturday that the Iranian regime is in a full-scale war with the...
US Airline Industry Caps a Strong 2025—What Lies Ahead in 2026
By Panos Mourdoukoutas Despite a shaky start earlier in the year, U.S. airline travel reached another milestone during the 2025...
What Trump’s National Security Strategy Means for Canada
By Noe Chartier Canada receives but a passing mention in the recently released U.S. National Security Strategy, but that doesn’t...
Italy Arrests 9 for Allegedly Using Charities to Fund Hamas Terrorists
By Tom Ozimek Italian authorities have arrested nine people on suspicion of financing Hamas through a network of charities operating...
Winter Weather Cancels Over 1,000 Flights Across US
By Jacki Thrapp Travelers may need to pack their patience on Dec. 27 as winter weather in the Northeast prompted...
Trump Says 2026 Midterms Will Be Referendum on Prices, Economic Success
By Tom Ozimek President Donald Trump said he expects the 2026 midterm elections to hinge on prices and perceptions of...